• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by BridgeBio Pharma Inc.

    7/29/25 11:20:32 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBIO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    Bridgebio Pharma Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    10806X102

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    10806X102


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    186,259.00
    7Sole Dispositive Power

    16,126,179.00
    8Shared Dispositive Power

    358,806.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    16,484,985.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.68 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Bridgebio Pharma Inc
    (b)Address of issuer's principal executive offices:

    3160 Porter Dr, Suite 250, Palo Alto, CA, 94304
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    10806X102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    16484985
    (b)Percent of class:

    8.68  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    186259

     (iii) Sole power to dispose or to direct the disposition of:

    16126179

     (iv) Shared power to dispose or to direct the disposition of:

    358806

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:07/29/2025
    Get the next $BBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBIO

    DatePrice TargetRatingAnalyst
    1/28/2026$157.00Overweight
    Barclays
    1/6/2026$96.00Overweight
    Morgan Stanley
    12/11/2025$94.00Outperform
    Bernstein
    7/30/2025$56.00Outperform
    Raymond James
    7/21/2025$66.00Buy
    Truist
    7/14/2025$70.00Buy
    Jefferies
    7/9/2025$60.00Perform → Outperform
    Oppenheimer
    6/17/2025$49.00Outperform
    Wolfe Research
    More analyst ratings

    $BBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on BridgeBio Pharma with a new price target

    Barclays initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $157.00

    1/28/26 7:16:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on BridgeBio Pharma with a new price target

    Morgan Stanley initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $96.00

    1/6/26 8:54:42 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on BridgeBio Pharma with a new price target

    Bernstein initiated coverage of BridgeBio Pharma with a rating of Outperform and set a new price target of $94.00

    12/11/25 9:03:51 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    SEC Filings

    View All

    BridgeBio Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - BridgeBio Pharma, Inc. (0001743881) (Filer)

    1/21/26 4:07:58 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - BridgeBio Pharma, Inc. (0001743881) (Filer)

    1/12/26 4:06:26 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BridgeBio Pharma Inc.

    144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

    1/8/26 4:23:17 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

    4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    6/30/25 5:49:25 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

    4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    6/30/25 5:46:18 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    2/13/24 4:00:10 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (NASDAQ:BBIO), please note that some of the figures in the first paragraph were incorrect. The corrected release follows: BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that on January 23, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 11 new employees in restricted stock units for an aggregate of 31,428 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted

    1/27/26 5:10:54 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that on January 23, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 12 new employees in restricted stock units for an aggregate of 34,199 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to e

    1/27/26 4:01:00 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

    The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturityOffering priced at 0.75% interest rate and 45% conversion premium PALO ALTO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (the "Company," "we" or "BridgeBio"), a new type of biopharmaceutical company focused on genetic diseases, announced today the pricing of $550 million aggregate principal amount of 0.75% convertible senior notes due 2033 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In connection with t

    1/16/26 1:00:02 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kumar Neil sold $6,043,168 worth of shares (80,000 units at $75.54) (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    1/12/26 9:01:29 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kumar Neil converted options into 60,975 shares, covered exercise/tax liability with 30,964 shares and sold $2,239,902 worth of shares (30,011 units at $74.64) (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    12/16/25 6:27:18 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CFO Trimarchi Thomas covered exercise/tax liability with 13,826 shares, decreasing direct ownership by 4% to 369,004 units (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    12/16/25 6:25:44 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Financials

    Live finance-specific insights

    View All

    BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

    -$120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue  -As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment  -Attruby continues to differentiate clinically by proving its unique profile in new subpopulations and holistic analyses:  -JACC publication demonstrated the effect of Attruby on cumulative cardiovascular outcomes within the first month of treatment    -Positive toplin

    10/29/25 4:01:00 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

    - The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints  - The primary endpoint was met with 76% of participants administered encaleret achieving both serum and urine calcium within the respective target ranges at Week 24 compared to 4% when on conventional therapy at Week 4 (p<0.0001) - In a key secondary analysis, 91% of participants administered encaleret achieved intact PTH above the lower limit of the reference range at Week 24 compared to 7% of participants when on conventional therapy at Week 4 (p<0.0001) - Encaleret was well-tolerated with no discontinuations related to study drug - NDA submission planned in th

    10/29/25 7:00:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

    PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced plans to release topline results of the autosomal dominant hypocalcemia type 1 (ADH1) CALIBRATE Phase 3 trial before the market opens on Wednesday, October 28, 2025. Members of management will host a conference call to discuss the data at 8:00 a.m. ET the same day. To access the live webcast for BridgeBio's calls, please visit the "Events and Presentations" page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be ava

    10/28/25 4:01:00 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    11/6/24 5:04:05 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    9/17/24 6:41:54 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    8/20/24 8:42:04 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Leadership Updates

    Live Leadership Updates

    View All

    BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

    PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized ope

    7/23/24 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

    The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commerci

    5/2/24 7:00:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors

    PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to the National Academy of Medicine in 2020 for her research in organ transplantation

    10/25/21 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care